FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1642946927> ?p ?o ?g. }

• W1642946927 endingPage "10620" @default.
• W1642946927 startingPage "10607" @default.
• W1642946927 abstract "// Catia Giovannini 1,2,* , Manuela Minguzzi 1,2,* , Michele Baglioni 1,2 , Francesca Fornari 1,2 , Ferdinando Giannone 1,2 , Matteo Ravaioli 3 , Matteo Cescon 3 , Pasquale Chieco 1 , Luigi Bolondi 1,2 and Laura Gramantieri 1 1 Center for Applied Biomedical Research (CRBA), S.Orsola-Malpighi University Hospital, Bologna, Italy 2 Department of Medical and Surgical Sciences University of Bologna, Bologna, Italy 3 Department of Medical and Surgical Sciences, General and Transplant Surgery Unit, University of Bologna, Bologna, Italy * These authors contributed equally to this work Correspondence: Catia Giovannini, email: // Keywords : Notch3, p53, miR-221, CyclinG1, MDM2 Received : June 18, 2014 Accepted : September 24, 2014 Published : September 25, 2014 Abstract To successfully target Notch receptors as part of a multidrug anticancer strategy, it will be essential to fully characterize the factors that are modulated by Notch signaling. We recently reported that Notch3 silencing in HCC results in p53 up-regulation in vitro and, therefore, we focused on the mechanisms that associate Notch3 to p53 protein expression. We explored the regulation of p53 by Notch3 signalling in three HCC cell lines HepG2, SNU398 and Hep3B.We found that Notch3 regulates p53 at post-transcriptional level controlling both Cyclin G1 expression and the feed-forward circuit involving p53, miR-221 and MDM2. Moreover, our results were validated in human HCCs and in a rat model of HCC treated with Notch3 siRNAs. Our findings are becoming an exciting area for further in-depth research toward targeted inactivation of Notch3 receptor as a novel therapeutic approach for increasing the drug-sensitivity, and thereby improving the treatment outcome of patients affected by HCC. Indeed, we proved that Notch3 silencing strongly increases the effects of Nutilin-3.With regard to therapeutic implications, Notch3-specific drugs could represent a valuable strategy to limit Notch signaling in the context of hepatocellular carcinoma over-expressing this receptor." @default.
• W1642946927 created "2016-06-24" @default.
• W1642946927 creator A5005639704 @default.
• W1642946927 creator A5008675423 @default.
• W1642946927 creator A5032016003 @default.
• W1642946927 creator A5032121417 @default.
• W1642946927 creator A5037793919 @default.
• W1642946927 creator A5068348071 @default.
• W1642946927 creator A5076619850 @default.
• W1642946927 creator A5078408743 @default.
• W1642946927 creator A5084312009 @default.
• W1642946927 creator A5085011734 @default.
• W1642946927 date "2014-09-25" @default.
• W1642946927 modified "2023-10-15" @default.
• W1642946927 title "Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma" @default.
• W1642946927 cites W1650797637 @default.
• W1642946927 cites W1823168351 @default.
• W1642946927 cites W1965173366 @default.
• W1642946927 cites W1966050487 @default.
• W1642946927 cites W1970820847 @default.
• W1642946927 cites W1990576890 @default.
• W1642946927 cites W1998443910 @default.
• W1642946927 cites W2050311403 @default.
• W1642946927 cites W2050981751 @default.
• W1642946927 cites W2057468718 @default.
• W1642946927 cites W2058734213 @default.
• W1642946927 cites W2068912983 @default.
• W1642946927 cites W2070300061 @default.
• W1642946927 cites W2074277756 @default.
• W1642946927 cites W2074545297 @default.
• W1642946927 cites W2076823393 @default.
• W1642946927 cites W2082979850 @default.
• W1642946927 cites W2084499174 @default.
• W1642946927 cites W2087438476 @default.
• W1642946927 cites W2089522893 @default.
• W1642946927 cites W2091145752 @default.
• W1642946927 cites W2092663839 @default.
• W1642946927 cites W2100448419 @default.
• W1642946927 cites W2105639434 @default.
• W1642946927 cites W2107515690 @default.
• W1642946927 cites W2113166966 @default.
• W1642946927 cites W2117348043 @default.
• W1642946927 cites W2123170459 @default.
• W1642946927 cites W2124323423 @default.
• W1642946927 cites W2126154059 @default.
• W1642946927 cites W2135094627 @default.
• W1642946927 cites W2136261989 @default.
• W1642946927 cites W2152993806 @default.
• W1642946927 cites W2169756921 @default.
• W1642946927 cites W2170494099 @default.
• W1642946927 cites W2182140362 @default.
• W1642946927 cites W3123908578 @default.
• W1642946927 cites W75583122 @default.
• W1642946927 cites W111204808 @default.
• W1642946927 doi "https://doi.org/10.18632/oncotarget.2523" @default.
• W1642946927 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4279397" @default.
• W1642946927 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25431954" @default.
• W1642946927 hasPublicationYear "2014" @default.
• W1642946927 type Work @default.
• W1642946927 sameAs 1642946927 @default.
• W1642946927 citedByCount "38" @default.
• W1642946927 countsByYear W16429469272015 @default.
• W1642946927 countsByYear W16429469272016 @default.
• W1642946927 countsByYear W16429469272017 @default.
• W1642946927 countsByYear W16429469272018 @default.
• W1642946927 countsByYear W16429469272019 @default.
• W1642946927 countsByYear W16429469272020 @default.
• W1642946927 countsByYear W16429469272021 @default.
• W1642946927 countsByYear W16429469272022 @default.
• W1642946927 countsByYear W16429469272023 @default.
• W1642946927 crossrefType "journal-article" @default.
• W1642946927 hasAuthorship W1642946927A5005639704 @default.
• W1642946927 hasAuthorship W1642946927A5008675423 @default.
• W1642946927 hasAuthorship W1642946927A5032016003 @default.
• W1642946927 hasAuthorship W1642946927A5032121417 @default.
• W1642946927 hasAuthorship W1642946927A5037793919 @default.
• W1642946927 hasAuthorship W1642946927A5068348071 @default.
• W1642946927 hasAuthorship W1642946927A5076619850 @default.
• W1642946927 hasAuthorship W1642946927A5078408743 @default.
• W1642946927 hasAuthorship W1642946927A5084312009 @default.
• W1642946927 hasAuthorship W1642946927A5085011734 @default.
• W1642946927 hasBestOaLocation W16429469271 @default.
• W1642946927 hasConcept C104317684 @default.
• W1642946927 hasConcept C119056186 @default.
• W1642946927 hasConcept C121608353 @default.
• W1642946927 hasConcept C126322002 @default.
• W1642946927 hasConcept C161879069 @default.
• W1642946927 hasConcept C170493617 @default.
• W1642946927 hasConcept C199835354 @default.
• W1642946927 hasConcept C2776192174 @default.
• W1642946927 hasConcept C2778019345 @default.
• W1642946927 hasConcept C2779314089 @default.
• W1642946927 hasConcept C29537977 @default.
• W1642946927 hasConcept C502942594 @default.
• W1642946927 hasConcept C54355233 @default.
• W1642946927 hasConcept C71924100 @default.
• W1642946927 hasConcept C81885089 @default.
• W1642946927 hasConcept C86803240 @default.

• next